Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | HCK | P08631 | 6/20 | 0.41 |
| ▸ | BTK | Q06187 | 6/20 | 0.41 |
| ▸ | LCK | P06239 | 11/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106051 | 0.92 | MAPK14 (0.46) | MAPK14HCKBTKLCKSRC | |
| SCHEMBL31705188 | 0.83 | LCK (0.52) | MAPK14HCKLCKSRCMAPK13 | |
| SCHEMBL31106019 | 0.82 | LCK (0.45) | MAPK14HCKBTKLCKSRC | |
| SCHEMBL31105900 | 0.82 | BTK (0.46) | HCKBTKLCKSRCABL1 | |
| SCHEMBL31105865 | 0.80 | LCK (0.46) | MAPK14HCKBTKLCKSRC | |
| SCHEMBL31105942 | 0.80 | LCK (0.42) | MAPK14HCKBTKLCKSRC | |
| SCHEMBL31105912 | 0.80 | MAPK14 (0.50) | MAPK14HCKBTKLCKSRC | |
| SCHEMBL31105893 | 0.79 | LCK (0.41) | MAPK14HCKLCKSRCMAPK13 | |
| SCHEMBL31106172 | 0.79 | BTK (0.47) | MAPK14HCKBTKLCKSRC | |
| SCHEMBL31105895 | 0.78 | LCK (0.44) | MAPK14HCKBTKLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024184520-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |